Sotera Health Company (NASDAQ:SHC) Given Average Rating of “Moderate Buy” by Brokerages

Sotera Health Company (NASDAQ:SHC) has been given a consensus rating of “Moderate Buy” by the six brokerages that are presently covering the firm, Marketbeat reports. Three analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $17.80.

A number of equities analysts have commented on SHC shares. Piper Sandler boosted their target price on shares of Sotera Health from $15.00 to $17.00 and gave the stock a “neutral” rating in a report on Wednesday, November 5th. Barclays boosted their price objective on shares of Sotera Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 5th. BMO Capital Markets initiated coverage on shares of Sotera Health in a research note on Thursday, November 13th. They issued an “outperform” rating and a $19.00 target price for the company. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Sotera Health in a research report on Wednesday. Finally, JPMorgan Chase & Co. raised their price objective on Sotera Health from $14.00 to $16.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 5th.

Insider Activity

In other news, Director Pincus & Co. Warburg sold 12,000,000 shares of the business’s stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $15.11, for a total transaction of $181,320,000.00. Following the sale, the director owned 61,822,952 shares in the company, valued at approximately $934,144,804.72. The trade was a 16.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gtcr Investment Xi Llc sold 12,000,000 shares of the company’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $15.65, for a total transaction of $187,800,000.00. Following the transaction, the director owned 29,215,301 shares in the company, valued at approximately $457,219,460.65. This trade represents a 29.12% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 32,000,000 shares of company stock valued at $490,000,000. Corporate insiders own 47.55% of the company’s stock.

Institutional Investors Weigh In On Sotera Health

A number of large investors have recently made changes to their positions in the stock. TPG GP A LLC acquired a new stake in Sotera Health during the 1st quarter worth about $79,126,000. Sculptor Capital LP boosted its position in Sotera Health by 80.8% in the first quarter. Sculptor Capital LP now owns 9,037,511 shares of the company’s stock valued at $105,377,000 after buying an additional 4,037,511 shares during the last quarter. Vanguard Group Inc. boosted its position in Sotera Health by 10.5% in the third quarter. Vanguard Group Inc. now owns 16,471,792 shares of the company’s stock valued at $259,101,000 after buying an additional 1,561,282 shares during the last quarter. Voss Capital LP increased its holdings in Sotera Health by 146.7% in the 3rd quarter. Voss Capital LP now owns 1,850,000 shares of the company’s stock worth $29,100,000 after buying an additional 1,100,000 shares during the period. Finally, Norges Bank purchased a new position in Sotera Health during the 2nd quarter worth approximately $9,607,000. 91.03% of the stock is owned by hedge funds and other institutional investors.

Sotera Health Stock Up 0.3%

Sotera Health stock opened at $17.49 on Friday. The company has a quick ratio of 2.18, a current ratio of 2.38 and a debt-to-equity ratio of 4.04. The firm has a market cap of $4.97 billion, a P/E ratio of 92.03 and a beta of 1.82. The business has a fifty day moving average of $16.21 and a two-hundred day moving average of $14.21. Sotera Health has a twelve month low of $9.53 and a twelve month high of $17.78.

Sotera Health (NASDAQ:SHC) last released its quarterly earnings results on Tuesday, November 4th. The company reported $0.26 EPS for the quarter, topping the consensus estimate of $0.22 by $0.04. The firm had revenue of $311.31 million during the quarter, compared to analyst estimates of $303.63 million. Sotera Health had a return on equity of 43.69% and a net margin of 4.82%. Sotera Health has set its FY 2025 guidance at 0.810-0.860 EPS. On average, analysts forecast that Sotera Health will post 0.61 earnings per share for the current fiscal year.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.